Zacks: Analysts Anticipate KITOV PHARMA LT/S (KTOV) to Post -$0.01 EPS
Brokerages forecast that KITOV PHARMA LT/S (NASDAQ:KTOV) will report earnings of ($0.01) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for KITOV PHARMA LT/S’s earnings. The business is expected to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that KITOV PHARMA LT/S will report full year earnings of ($0.03) per share for the current financial year. For the next year, analysts anticipate that the firm will post earnings of ($0.02) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow KITOV PHARMA LT/S.
A number of research analysts recently weighed in on the company. Zacks Investment Research upgraded KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Friday, June 15th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of KITOV PHARMA LT/S in a report on Wednesday, June 6th.
About KITOV PHARMA LT/S
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
Further Reading: What is a stock buyback?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.